COIOSDeep risk insights through multi-disciplinary research across the globe
TrackerUpdated

GLP-1 prescribing

GLP-1 medicines each month, by drug, as published - NHS prescription items in England and the number of users in Denmark. Data as of 9 November 2026.

tirzepatide (Mounjaro)semaglutide (Ozempic, Wegovy, Rybelsus)dulaglutide (Trulicity)liraglutide (Victoza, Saxenda and generics)Wegovy (semaglutide)Ozempic (semaglutide)Mounjaro (tirzepatide)Saxenda (liraglutide)

England

items per month · data to Aug 2026
342,252tirzepatide (Mounjaro)
144,757semaglutide (Ozempic, Wegovy, Rybelsus)
37,162dulaglutide (Trulicity)
1,408liraglutide (Victoza, Saxenda and generics)
0100k200k300k400k202120222023202420252026

NHS Business Services Authority: NHS prescription items written in England and dispensed in the community in the month, summed over all prescribers for each BNF chemical substance (tablets and injections of a drug counted together); private prescriptions and hospital-dispensed medicines are not included

Released 20 Oct 2026

Denmark

users per month · data to Sep 2026
102,360Wegovy (semaglutide)
69,828Ozempic (semaglutide)
6,721Mounjaro (tirzepatide)
428Saxenda (liraglutide)
050k100k150k202120222023202420252026

Danish Health Data Authority: people who bought the product on prescription in the month in primary care, all sales including private, by product (Wegovy and Ozempic are both semaglutide, Mounjaro is tirzepatide, Saxenda is liraglutide); figures the authority suppresses (fewer than 5) are left without a figure

Released 9 Nov 2026 · next 8 Dec 2026

Revised by the source: 3 earlier weeks since 16 Oct 2026; the largest, the week to Aug 2026, from 6,530 to 6,564

GLP-1 medicines per month, as published. England counts NHS prescription items by drug and leaves out private prescriptions; Denmark counts the people who bought each product in the month, private sales included. The two measure different things and each card has its own scale. Neither records the indication, so use for diabetes and for weight management are counted together.
DrugLatest monthFigureMonth beforeChange on month beforeSource release
England, tirzepatide (Mounjaro)Aug 2026342,252 items367,597 items-6.9%20 Oct 2026
England, semaglutide (Ozempic, Wegovy, Rybelsus)Aug 2026144,757 items154,448 items-6.3%20 Oct 2026
England, dulaglutide (Trulicity)Aug 202637,162 items42,098 items-11.7%20 Oct 2026
England, liraglutide (Victoza, Saxenda and generics)Aug 20261,408 items1,587 items-11.3%20 Oct 2026
Denmark, Wegovy (semaglutide)Sep 2026102,360 users106,600 users-4.0%9 Nov 2026
Denmark, Ozempic (semaglutide)Sep 202669,828 users69,153 users+1.0%9 Nov 2026
Denmark, Mounjaro (tirzepatide)Sep 20266,721 users6,564 users+2.4%9 Nov 2026
Denmark, Saxenda (liraglutide)Sep 2026428 users410 users+4.4%9 Nov 2026

Download the whole series: CSV · JSON, with every release collected

Method note

The figures are NHS prescription items for four GLP-1 receptor agonists — tirzepatide, semaglutide, dulaglutide and liraglutide — written in England and dispensed in the community each month, as published by the NHS Business Services Authority. An item is one drug on one prescription form. It is not a patient, and one patient may have several items in a month. Tablets and injections of the same drug are counted together, because the source records the drug and not the form at this level.

Two things sit outside these figures. Private prescriptions are not in the dataset, and in the United Kingdom most tirzepatide supplied for weight loss has been private. A prescription also records no indication, so use for type 2 diabetes and use for weight management cannot be separated: Mounjaro, generic tirzepatide and semaglutide serve both.

The SNOMED edition of the dataset begins in November 2020. Each month is published about seven weeks after it ends. The latest three months are read again on every run, so any revision the NHS Business Services Authority makes is recorded below.

Denmark's figures are the Danish Health Data Authority's count of people who bought each product on prescription in primary care in the month, from its monthly publication on weight-loss and diabetes medicines. They include privately paid prescriptions. They are given by brand — Wegovy and Ozempic are both semaglutide, Mounjaro is tirzepatide, Saxenda is liraglutide — and counts of fewer than five are suppressed by the authority. People are counted, not prescriptions, so Denmark's figures cannot be set against England's items. Each card has its own scale.

Sources and licences

The Netherlands publishes GLP-1 use by year (GIPdatabank), Germany quarterly reports in PDF and the United States quarterly Medicaid data, so they are not in this tracker.

Revisions

Changes a source has made to its own past figures since this tracker began collecting.

  • 10 Nov 2026, Denmark, Wegovy (semaglutide): 2 earlier period(s) revised; the largest change was Feb 2026, from 101,828 to 101,961.
  • 10 Nov 2026, Denmark, Ozempic (semaglutide): 2 earlier period(s) revised; the largest change was Feb 2026, from 56,561 to 56,605.
  • 10 Nov 2026, Denmark, Mounjaro (tirzepatide): 2 earlier period(s) revised; the largest change was Feb 2026, from 4,620 to 4,625.
  • 16 Oct 2026, Denmark, Wegovy (semaglutide): 1 earlier period(s) revised; the largest change was Aug 2026, from 106,332 to 106,600.
  • 16 Oct 2026, Denmark, Saxenda (liraglutide): 1 earlier period(s) revised; the largest change was Aug 2026, from 409 to 410.
  • 16 Oct 2026, Denmark, Ozempic (semaglutide): 1 earlier period(s) revised; the largest change was Aug 2026, from 68,965 to 69,153.
  • 16 Oct 2026, Denmark, Mounjaro (tirzepatide): 1 earlier period(s) revised; the largest change was Aug 2026, from 6,530 to 6,564.

Download

CSV of the whole series · JSON, with every release collected